A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we rep...

Full description

Saved in:
Bibliographic Details
Main Authors: Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher S. Lathan, Judith Marcoux, Jinyan Du, Katsuhiro Okuda, Marzia Capelletti, Takeshi Shimamura, Dalia Ercan, Magda Stumpfova, Yun Xiao, Stanislawa Weremowicz, Mohit Butaney, Stéphanie Héon, Keith D. Wilner, James G. Christensen, Michel J. Eck, Kwok‐Kin Wong, Neal I. Lindeman, Nathanael S. Gray, Scott J. Rodig, Pasi A. Jänne
Format: Artigo
Language:English
Published: 2011
Online Access:https://doi.org/10.1158/0008-5472.can-11-1340
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1158/0008-5472.can-11-1340

Similar Items